17-46923195-G-T
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1PS1_ModeratePM2
The NM_004287.5(GOSR2):c.3G>T(p.Met1?) variant causes a start lost change. The variant allele was found at a frequency of 0.000000717 in 1,394,166 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: not found (cov: 33)
Exomes 𝑓: 7.2e-7 ( 0 hom. )
Consequence
GOSR2
NM_004287.5 start_lost
NM_004287.5 start_lost
Scores
4
6
1
Clinical Significance
Conservation
PhyloP100: 4.51
Genes affected
GOSR2 (HGNC:4431): (golgi SNAP receptor complex member 2) This gene encodes a trafficking membrane protein which transports proteins among the medial- and trans-Golgi compartments. Due to its chromosomal location and trafficking function, this gene may be involved in familial essential hypertension. [provided by RefSeq, Mar 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PVS1
?
Start lost variant, no new inframe start found.
PS1
?
Another start lost variant in NM_004287.5 (GOSR2) was described as [Pathogenic] in ClinVar as 1324496
PM2
?
Very rare variant in population databases, with high coverage;
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
GOSR2 | NM_004287.5 | c.3G>T | p.Met1? | start_lost | 1/6 | ENST00000640051.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
GOSR2 | ENST00000640051.2 | c.3G>T | p.Met1? | start_lost | 1/6 | 1 | NM_004287.5 | P3 |
Frequencies
GnomAD3 genomes ? Cov.: 33
GnomAD3 genomes
?
Cov.:
33
GnomAD4 exome AF: 7.17e-7 AC: 1AN: 1394166Hom.: 0 Cov.: 30 AF XY: 0.00000145 AC XY: 1AN XY: 687936
GnomAD4 exome
AF:
AC:
1
AN:
1394166
Hom.:
Cov.:
30
AF XY:
AC XY:
1
AN XY:
687936
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome ? Cov.: 33
GnomAD4 genome
?
Cov.:
33
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
Progressive myoclonic epilepsy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Invitae | Aug 22, 2022 | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Disruption of the initiator codon has been observed in individual(s) with clinical features of GOSR2-related conditions (PMID: 29855340). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is not present in population databases (gnomAD no frequency). This sequence change affects the initiator methionine of the GOSR2 mRNA. The next in-frame methionine is located at codon 19. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
Cadd
Benign
Dann
Uncertain
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D;D;D;D;D;D;D;D;D;D;D;D;D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D;D;D;D;D;D;D;D;D;D
MetaSVM
Uncertain
T
MutationTaster
Benign
D;D;D;D;D;D
Polyphen
0.89, 0.32
.;.;.;P;.;.;B;.;.;.;.;.;.;.
Vest4
0.78, 0.78, 0.79, 0.77
MutPred
Gain of catalytic residue at M1 (P = 0.0328);Gain of catalytic residue at M1 (P = 0.0328);Gain of catalytic residue at M1 (P = 0.0328);Gain of catalytic residue at M1 (P = 0.0328);Gain of catalytic residue at M1 (P = 0.0328);Gain of catalytic residue at M1 (P = 0.0328);Gain of catalytic residue at M1 (P = 0.0328);Gain of catalytic residue at M1 (P = 0.0328);Gain of catalytic residue at M1 (P = 0.0328);Gain of catalytic residue at M1 (P = 0.0328);Gain of catalytic residue at M1 (P = 0.0328);Gain of catalytic residue at M1 (P = 0.0328);Gain of catalytic residue at M1 (P = 0.0328);Gain of catalytic residue at M1 (P = 0.0328);
MVP
0.82
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at